IMAXIO is an integrated biotech company focused on vaccines, and based on the combination of commercial and R&D activities:

R&D PIPELINE BASED ON THE IMX313 TECHNOLOGY PLATFORM: an antigen re-engineering platform to improve their immunogenicity, to develop more effective vaccines & immunotherapies.

PHARMACEUTICAL PRODUCTS: a vaccine against human leptospirosis and an orphan drug indicated in Wilson disease, both of them marketed in France.


IMAXIO’s main objective is to develop its R&D projects up to phase I / phase II clinical trials, to be out-licensed to biopharmaceutical companies able to push forward the related vaccines & immunotherapies development up to phase III and commercialization.

In order to support such R&D efforts, IMAXIO commercializes two niche pharmaceuticals which generate around 2 M€.

IMAXIO remains opened to new collaborations, with partners having know-how on antigens poorly immunogenic in therapeutic indication not already targeted by IMAXIO.

IMAXIO was developed as a spin-off of the Medical Research Council and the University of Cambridge (United-Kingdom).